| Rank | Title | Journal | Year | PubWeight™‹?› |
|---|---|---|---|---|
| 1 | Modulation of lymphocyte regulation for cancer therapy: a phase II trial of tremelimumab in advanced gastric and esophageal adenocarcinoma. | Clin Cancer Res | 2010 | 1.14 |
| 2 | Killing of non-Hodgkin lymphoma cells by autologous CD19 engineered T cells. | Br J Haematol | 2005 | 1.00 |
| 3 | Tremelimumab (anti-CTLA4) mediates immune responses mainly by direct activation of T effector cells rather than by affecting T regulatory cells. | Clin Immunol | 2010 | 0.99 |
| 4 | Anti-angiogenic therapy in the treatment of advanced renal cell cancer. | Cancer Treat Rev | 2006 | 0.81 |